Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Interview with Dr. Bishal Gyawali from the Institute of Cancer Policy, London and Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital

Name: Interview with Interview with Dr. Bishal Gyawali from the Institute of Cancer Policy, London and Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital
Uploaded: 2022-02-15
Duration: 7 min 58 s
Description: Interview regarding their article published in Oncotarget Volume 8, Issue 52 titled Cancer drugs in LMICs: cheap but unaffordable

Dr. Bishal Gyawali from the Institute of Cancer Policy, London and Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, discusses an editorial he authored that was published by Oncotarget in Volume 8, Issue 52, entitled, "Cancer drugs in LMICs: cheap but unaffordable."

DOI - https://doi.org/10.18632/oncotarget.21976

Full text - https://www.oncotarget.com/article/21976/

Correspondence to - Bishal Gyawali - [email protected]

Keywords - value, affordability, global oncology, drug prices, cancer

Publication Alerts

Interview with Dr. Bishal Gyawali from the Institute of Cancer Policy, London and Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital